Corteva, Inc. CTVA · NYSE
$12.64 -1.86% (-$0.24)
Summary
72 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $1.07B in the last fiscal year, 13% of its market value.
- It has raised its dividend 5 years in a row and pays out only 48% of profit.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.4 USD for 1 USD of yearly profit. Over the last five years it was 37.7 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 4.1% a year over 5 years. Over the last 3 years it fell by 0.1% a year. For the next fiscal year analysts expect revenue to grow by 0.6%. Earnings per share grew by 0.4% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 52 USD
- Research and development 8.4 USD
- Sales and administration 23 USD
- Taxes and other 11 USD
- Net profit 5.7 USD
Net profit, industry median (Agricultural Inputs) 5.7 USD
Out of every 100 USD of revenue, 5.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.8 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
High, stretched- Yield
- 5.70%
- Paid out of profit
- 48%
- Raised in a row
- 5 years
You receive $0.72 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 25
- Hold 10
- Sell 2
Today's price within the analysts' price targets
The average target of $49.17 is 289% above today's price. 68% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Seed 40%
- Crop Protection 30%
- Herbicides 15%
- Insecticides 6.7%
- Fungicides 4.6%
- Other 3.9%
By region
- UNITED STATES 41%
- Latin America 19%
- EMEA 15%
- BRAZIL 14%
- Asia Pacific 6.6%
- Other 3.7%
Seed brings in 40% of revenue. Crop Protection grew fastest, by 18% a year.
Segments in detail